Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | CTSA | P10619 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711978 | 0.81 | PKM (0.38) | ALDH1A1PKMCTSASLC6A2SLC6A4 | |
| Butane SCHEMBL7565121 | 0.80 | CTSA (0.34) | ALDH1A1PKMCTSASLC6A2SLC6A4 | |
| SCHEMBL7565127 | 0.79 | TSHR (0.37) | ALDH1A1PKMCTSALMNAKDM4E | |
| SCHEMBL8613951 | 0.73 | CTSA (0.36) | ALDH1A1PKMCTSASLC6A2SLC6A4 | |
| SCHEMBL1975745 | 0.72 | FBP1 (0.39) | ALDH1A1CTSASLC6A2SLC6A4FBP1 | |
| SCHEMBL21010058 | 0.72 | FBP1 (0.36) | ALDH1A1CTSASLC6A2SLC6A4FBP1 | |
| SCHEMBL12041576 | 0.72 | FBP1 (0.36) | ALDH1A1CTSASLC6A2SLC6A4FBP1 | |
| SCHEMBL8429804 | 0.72 | ALDH1A1 (0.51) | ALDH1A1PKMCTSALMNANPC1 | |
| SCHEMBL4312352 | 0.71 | — | — | |
| SCHEMBL9990775 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108285444-A | A kind of preparation method of thiazole | 湖南华腾制药有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-107778304-A | A kind of preparation method of thiazole | 湖南华腾制药有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-7910579-B2 | Benzoxazole derivatives | TOHOKU UNIVERSITY (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910579-B2 | Benzoxazole derivatives | TOHOKU UNIVERSITY (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100021385-A1 | BENZOXAZOLE DERIVATIVES | TOHOKU UNIVERSITY (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100021385-A1 | BENZOXAZOLE DERIVATIVES | TOHOKU UNIVERSITY (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALDH1A1 1072/4885PKM 3521/4885CTSA 3757/4885 |
| US-20100021385-A1 | BENZOXAZOLE DERIVATIVES | CBX7, KIT, BMX | ALDH1A1 1195/4885PKM 485/4885CTSA 1900/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALDH1A1 1016/4885PKM 3207/4885CTSA 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.